dc.creator | Moreira Soto, Andrés | |
dc.creator | Gutiérrez, José María | |
dc.creator | Alape Girón, Alberto | |
dc.creator | Drexler, Jan Felix | |
dc.creator | Arguedas Gómez, Mauricio | |
dc.creator | Brenes Porras, Hebleen | |
dc.creator | Buján Boza, Willem Aart | |
dc.creator | Corrales Aguilar, Eugenia | |
dc.creator | Díaz Oreiro, Cecilia | |
dc.creator | Echeverri McCandless, Ann | |
dc.creator | Flores Díaz, Marietta | |
dc.creator | Macaya Hayes, Román | |
dc.creator | Kühne, Arne | |
dc.creator | Molina Mora, José Arturo | |
dc.creator | Mora Rodríguez, Javier Francisco | |
dc.creator | Sanabria Castro, Alfredo | |
dc.creator | Sánchez Brenes, Andrés | |
dc.creator | Sánchez Céspedes, Laura Vanessa | |
dc.creator | Segura Ruiz, Álvaro | |
dc.creator | Segura Agüero, Eduardo | |
dc.creator | Solano Centeno, Daniela | |
dc.creator | Soto Garita, Claudio | |
dc.creator | Stynoski, Jennifer Lynn | |
dc.creator | Vargas Arroyo, Mariángela | |
dc.creator | Villalta Arrieta, Mauren | |
dc.creator | Reusken, Chantal B. E. M. | |
dc.creator | Drosten, Christian | |
dc.date.accessioned | 2022-03-01T21:11:08Z | |
dc.date.available | 2022-03-01T21:11:08Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | https://www.frontiersin.org/articles/10.3389/fmed.2021.735853/full | es_ES |
dc.identifier.issn | 2296-858X | |
dc.identifier.uri | https://hdl.handle.net/10669/85930 | |
dc.description.abstract | SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and
therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We
tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical
trials in Costa Rica against five globally circulating variants of concern: alpha, beta,
epsilon, gamma and delta, using plaque reduction neutralization assays. We show that
equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations
in the range of 0.146–1.078µg/mL, which correspond to extremely low concentrations
when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad
coverage, low-cost and a scalable COVID-19 treatment. | es_ES |
dc.description.sponsorship | German academic exchange services/[57592642]/DAAD/Alemania | es_ES |
dc.description.sponsorship | Universidad de Costa Rica/[741-C0-198]/UCR/Costa Rica | es_ES |
dc.description.sponsorship | Banco Centroamericano de Integración Económica/[]/BCIE/Costa Rica | es_ES |
dc.language.iso | eng | es_ES |
dc.source | Frontiers in Medicine, vol.8, pp.1-4. | es_ES |
dc.subject | Equine antibodies | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | Therapy | es_ES |
dc.subject | Variant of concern | es_ES |
dc.subject | PRNT titers 50 | es_ES |
dc.subject | Neutralization test | es_ES |
dc.subject | COVID-19 | es_ES |
dc.subject | VIROLOGÍA | es_ES |
dc.title | High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern | es_ES |
dc.type | artículo original | es_ES |
dc.identifier.doi | 10.3389/fmed.2021.735853 | |
dc.description.procedence | UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Centro de Investigación en Enfermedades Tropicales (CIET) | es_ES |
dc.description.procedence | UCR::Vicerrectoría de Docencia::Salud::Facultad de Microbiología | es_ES |
dc.description.procedence | UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP) | es_ES |
dc.description.procedence | UCR::Vicerrectoría de Docencia::Salud::Facultad de Medicina::Escuela de Medicina | es_ES |
dc.identifier.codproyecto | 741-C0-198 | |